U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C13H15N3O4S
Molecular Weight 309.3425
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GLYMIDINE

SMILES

COCCOc1cnc(nc1)NS(=O)(=O)c2ccccc2

InChI

InChIKey=QFWPJPIVLCBXFJ-UHFFFAOYSA-N
InChI=1S/C13H15N3O4S/c1-19-7-8-20-11-9-14-13(15-10-11)16-21(17,18)12-5-3-2-4-6-12/h2-6,9-10H,7-8H2,1H3,(H,14,15,16)

HIDE SMILES / InChI
Molecular Formula C13H15N3O4S
Molecular Weight 309.3425
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Glymidine (Glycodiazine ) is a hypoglycaemic agent which has been introduced as a possible alternative to the sulphonylurea as and biguanides for the oral treatment of diabetes mellitus. It is one of a group of lipid soluble sulphapyrimidine derivatives synthesized by Gutsche et al. and bears some structural resemlance to tolbutamide. Its mode of action is similar to that of the sulphonylureas in that it appears to stimulate insulin release from the pancreas. Glycodiazine likely binds to ATP-sensitive potassium channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Membrane depolarization stimulates calcium ion influx through voltage-sensitive calcium channels. This increase in intracellular calcium ion concentration induces the secretion of insulin. It is used for the concomitant use with insulin for the treatment of noninsulin-dependent (type 2) diabetes mellitus. Glycodiazine is used concomitantly with insulin for the treatment of noninsulin-dependent (type 2) diabetes mellitus.

Originator

Approval Year

Unknown
109281
Targets

Targets

Primary TargetPharmacologyConditionPotency
ATP-sensitive inward rectifier potassium channel 1
7
Target ID: P48048
Gene ID: 3758.0
Gene Symbol: KCNJ1
Target Organism: Homo sapiens (Human)
Binding Agent
996
PubMed

PubMed

TitleDatePubMed
[Diabetes mellitus of elderly patients: therapeutic recommendations].
2008 Nov
Patents

Patents

3275635
2

Sample Use Guides

In Vivo Use Guide
Curator's Comment:: Most authors have limited the dose to 1.5g daily, but in the absence of side-effects it would seem reasonable to increase this dose when it has proved inadequate to produce good control.
The potency of glymidine is possibly slightly greater than tolbutamide, the average dose being 0.5g given twice daily, with a range of from 0.5g to 1.5g daily.
Route of Administration: Oral
In Vitro Use Guide
Glymidine exerted photohemolysis in the concentration 10(-4) mol/l
Substance Class Chemical
Created
by admin
on Sat Jun 26 05:05:20 UTC 2021
Edited
by admin
on Sat Jun 26 05:05:20 UTC 2021
Record UNII
4C5I4BQZ8F
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
GLYMIDINE
MI   WHO-DD  
Common Name English
(N-(5-(2-METHOXYETHOXY)-2-PYRIMIDINYL)BENZENESULFONAMIDO)
Common Name English
BENZENESULFONAMIDE, N-(5-(2-METHOXYETHOXY)-2-PYRIMIDINYL)-
Systematic Name English
GLYCODIAZINE
Common Name English
GLYMIDINE [MI]
Common Name English
GLIDIAZINE
Common Name English
GLYMIDINE [WHO-DD]
Common Name English
Classification Tree Code System Code
WHO-ATC A10BC01
Created by admin on Sat Jun 26 05:05:20 UTC 2021 , Edited by admin on Sat Jun 26 05:05:20 UTC 2021
NCI_THESAURUS C29711
Created by admin on Sat Jun 26 05:05:20 UTC 2021 , Edited by admin on Sat Jun 26 05:05:20 UTC 2021
WHO-VATC QA10BC01
Created by admin on Sat Jun 26 05:05:20 UTC 2021 , Edited by admin on Sat Jun 26 05:05:20 UTC 2021
Code System Code Type Description
DRUG BANK
DB01382
Created by admin on Sat Jun 26 05:05:20 UTC 2021 , Edited by admin on Sat Jun 26 05:05:20 UTC 2021
PRIMARY
RXCUI
102848
Created by admin on Sat Jun 26 05:05:20 UTC 2021 , Edited by admin on Sat Jun 26 05:05:20 UTC 2021
PRIMARY RxNorm
EPA CompTox
339-44-6
Created by admin on Sat Jun 26 05:05:20 UTC 2021 , Edited by admin on Sat Jun 26 05:05:20 UTC 2021
PRIMARY
EVMPD
SUB02387MIG
Created by admin on Sat Jun 26 05:05:20 UTC 2021 , Edited by admin on Sat Jun 26 05:05:20 UTC 2021
PRIMARY
MERCK INDEX
M5813
Created by admin on Sat Jun 26 05:05:20 UTC 2021 , Edited by admin on Sat Jun 26 05:05:20 UTC 2021
PRIMARY Merck Index
ECHA (EC/EINECS)
206-426-5
Created by admin on Sat Jun 26 05:05:20 UTC 2021 , Edited by admin on Sat Jun 26 05:05:20 UTC 2021
PRIMARY
WIKIPEDIA
Glymidine
Created by admin on Sat Jun 26 05:05:20 UTC 2021 , Edited by admin on Sat Jun 26 05:05:20 UTC 2021
PRIMARY
NCI_THESAURUS
C72805
Created by admin on Sat Jun 26 05:05:20 UTC 2021 , Edited by admin on Sat Jun 26 05:05:20 UTC 2021
PRIMARY
MESH
C073263
Created by admin on Sat Jun 26 05:05:20 UTC 2021 , Edited by admin on Sat Jun 26 05:05:20 UTC 2021
PRIMARY
PUBCHEM
9565
Created by admin on Sat Jun 26 05:05:20 UTC 2021 , Edited by admin on Sat Jun 26 05:05:20 UTC 2021
PRIMARY
FDA UNII
4C5I4BQZ8F
Created by admin on Sat Jun 26 05:05:20 UTC 2021 , Edited by admin on Sat Jun 26 05:05:20 UTC 2021
PRIMARY
DRUG CENTRAL
1321
Created by admin on Sat Jun 26 05:05:20 UTC 2021 , Edited by admin on Sat Jun 26 05:05:20 UTC 2021
PRIMARY
CAS
339-44-6
Created by admin on Sat Jun 26 05:05:20 UTC 2021 , Edited by admin on Sat Jun 26 05:05:20 UTC 2021
PRIMARY
Related Record Type Details
Structure of GLYMIDINE SODIUM
SALT/SOLVATE -> PARENT
ATP-BINDING CASSETTE SUB-FAMILY C MEMBER 8
TARGET -> INHIBITOR
Related Record Type Details
Structure of GLYMIDINE
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966